Neuronetics (STIM) EVP sells shares to cover RSU tax withholding

Rhea-AI Filing Summary

Neuronetics, Inc. executive William Andrew Macan, EVP, CLO and CS, reported selling 3,485 shares of common stock on February 10, 2026. The Form 4 notes these were non-discretionary sales made solely to satisfy tax withholding on the vesting of a restricted stock unit award, at a weighted average price of $1.55 per share. After this transaction, Macan directly beneficially owned 687,681 shares of Neuronetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACAN WILLIAM ANDREW

(Last) (First) (Middle)

C/O NEURONETICS, INC.

3222 PHOENIXVILLE PIKE

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CLO and CS

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		S		3,485(1)	D	$1.55(2)	687,681	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were non-discretionary sales to satisfy the Reporting Person's tax withholding obligation upon vesting of a portion of a restricted stock unit award.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $1.45 to $1.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Patrick Devine, as Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Neuronetics (STIM) report for William Andrew Macan?

Neuronetics reported that EVP, CLO and CS William Andrew Macan sold 3,485 shares of common stock on February 10, 2026. The filing states these were non-discretionary sales to cover tax withholding arising from the vesting of a restricted stock unit award.

At what price did William Andrew Macan sell Neuronetics (STIM) shares?

The reported sale used a weighted average price of $1.55 per share. Footnotes explain the shares were sold in multiple trades, with individual prices ranging from $1.45 to $1.60, to satisfy tax withholding obligations on a restricted stock unit vesting.

How many Neuronetics (STIM) shares does William Andrew Macan own after this Form 4?

Following the reported transaction, William Andrew Macan beneficially owned 687,681 shares of Neuronetics common stock directly. This figure reflects his holdings after the 3,485-share sale that was made to cover tax withholding from restricted stock unit vesting.

Why were Neuronetics (STIM) shares sold by William Andrew Macan according to the Form 4?

The Form 4 explains the sales were non-discretionary and executed solely to satisfy Macan’s tax withholding obligation. This obligation arose when a portion of a restricted stock unit (RSU) award vested, triggering required tax payments covered by the share sale.

What do the price range details mean in the Neuronetics (STIM) Form 4 filing?

The filing notes the reported $1.55 price is a weighted average. The 3,485 shares were sold in multiple transactions with per-share prices between $1.45 and $1.60. Macan undertakes to provide full trade-by-trade pricing details upon request to regulators or shareholders.

What is William Andrew Macan’s role at Neuronetics (STIM) mentioned in the Form 4?

The Form 4 identifies William Andrew Macan as an officer of Neuronetics, serving as EVP, CLO and CS. This indicates he is the Executive Vice President, Chief Legal Officer, and Corporate Secretary, and the transaction reflects his personal share ownership activity.